The biotech company also has a partnership with Sanofi (SNY) for the development, manufacture and commercialization of IgM antibody agonists against inflammation and immunology targets.

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Imvotamab is a T cell engaging antibody that targets CD20 and CD3 proteins. IGM Biosciences was evaluating it in three trials, the third being a treatment for myositis, a rare autoimmune disease ...

Red cell alloantibodies are primarily IgG and less often IgM. IgM antibodies readily fix complement and it is these that classically cause the intravascular AHTR. IgG antibodies typically cause ...

develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment ...

develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment ...

High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...